"There are already over 80 diseases and conditions that have been treated with cord blood stem cells," said Americord CEO Martin Smithmyer. "And every day, all around the world, researchers continue to pursue new medical uses of stem cells. We are inspired by their dedication and committed to helping today’s parents open up these potential medical options for their children, should they ever need them."
As a national leader in cord blood banking, Americord Registry has led the way in developing techniques and practices designed to best collect, process, and store stem cells from cord blood for purposes of future medical use. The company offers parents-to-be the ability to effectively preserve stem cells from umbilical cord blood, cord tissue, and placenta tissue. Americord plans to launch a proprietary product, called CordAdvantage, which will harvest stem cells from the cord blood found in the placenta.
About Americord Registry
Americord Registry, one of the fastest growing cord blood banks, is a leader in the advancement of umbilical cord blood, cord tissue and placenta tissue banking. Americord collects, processes, and stores newborn stem cells from umbilical cord blood for future medical or therapeutic use, including the treatment of more than 80 blood diseases such as sickle cell anemia and leukemia. Founded in 2008, Americord is registered with the FDA and operates in all 50 states. The company’s laboratory is CLIA Certified, accredited by the AABB and complies with all federal and state guidelines and applicable licenses. Americord is headquartered in New York, NY. You may visit Americord Registry’s website at http://cordadvantage.com/ for more information. You may also find Americord Registry on Facebook and follow the company on Twitter. GET IN TOUCH
Americord Registry LLC
Americord Applauds Promising Research Results Into The Treatment Of Hurler Syndrome With Umbilical Cord Blood Stem Cells This press release was distributed by prleap.com